The genomic landscape of CYP2D6 variation in the Indian population

References

• 1. Nelson DR, Kamataki T, Waxman DJ et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 12, 1–51 (1993).
  Medline CASGoogle Scholar
• 2. Gaedigk A, Ingelman-Sundberg M, Miller NA, Leeder JS, Whirl-Carrillo M, Klein TE. The Pharmacogene Variation (PharmVar) Consortium: incorporation of the human cytochrome P450 (CYP) allele nomenclature database. Clin. Pharmacol. Ther. 103, 399–401 (2018).
  Medline CASGoogle Scholar
• 3. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am. J. Hum. Genet. 45, 889 (1989).
  Medline CASGoogle Scholar
• 4. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am. J. Hum. Genet. 48, 943 (1991).
  Medline CASGoogle Scholar
• 5. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J. Biol. Chem. 265, 17209–17214 (1990).
  Medline CASGoogle Scholar
• 6. Bertilsson L, Dahl ML, Dalén P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol. 53, 111 (2002).
  Medline CASGoogle Scholar
• 7. Daly AK. Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: review of current knowledge and comparison with selected European populations. Drug Metab. Pers Ther. 30, 165–174 (2015).
  Medline CASGoogle Scholar
• 8. Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Steven Leeder J. Prediction of CYP2D6 phenotype from genotype across world populations. Genet. Med. 19, 69 (2017).
  MedlineGoogle Scholar
• 9. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet. Genomics 17, 93–101 (2007).
  Medline CASGoogle Scholar
• 10. Llerena A, Dorado P, Ramírez R et al. CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans. Pharmacogenomics J. 12, 176–183 (2012).
  Medline CASGoogle Scholar
• 11. Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin. Pharmacol. Ther. 102, 688 (2017).
  Medline CASGoogle Scholar
• 12. Del Tredici AL, Malhotra A, Dedek M et al. Frequency of CYP2D6 alleles including structural variants in the United States. Front. Pharmacol. 9, 305 (2018).
  MedlineGoogle Scholar
• 13. Naveen AT, Adithan C, Soya SS, Gerard N, Krishnamoorthy R. CYP2D6 genetic polymorphism in South Indian populations. Biol. Pharm. Bull. 29, 1655–1658 (2006).
  MedlineGoogle Scholar
• 14. Adithan C, Gerard N, Naveen AT, Koumaravelou K, Shashindran CH, Krishnamoorthy R. Genotype and allele frequency of CYP2D6 in Tamilian population. Eur. J. Clin. Pharmacol. 59, 517–520 (2003).
  Medline CASGoogle Scholar
• 15. Umamaheswaran G, Krishna Kumar D, Adithan C. Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters – a review with Indian perspective. Indian J. Med. Res. 139, 27 (2014).
  Medline CASGoogle Scholar
• 16. Choudhury S, Akam E, Mastana S. Genetic analysis of CYP2D6 polymorphism in Indian populations and its pharmacogenetic implications. Curr. Pharmacogenomics Person. Med. 12, 123–132 (2015).
  Google Scholar
• 17. Paradkar MU, Shah SAV, Dherai AJ, Shetty D, Ashavaid TF. Distribution of CYP2D6 genotypes in the Indian population – preliminary report. Drug Metab. Pers. Ther. 33, 141–151 (2018).
  Medline CASGoogle Scholar
• 18. Lamba V, Lamba JK, Dilawari JB, Kohli KK. Genetic polymorphism of CYP2D6 in North Indian subjects. Eur. J. Clin. Pharmacol. 54, 787–791 (1998).
  Medline CASGoogle Scholar
• 19. Abraham BK, Adithan C, Usha Kiran P, Asad M, Koumaravelou K. Genetic polymorphism of CYP2D6 in Karnataka and Andhra Pradesh population in India. Acta Pharmacol. Sin. 21, 494–498 (2000).
  Medline CASGoogle Scholar
• 20. Jain A, Bhoyar RC, Pandhare K et al. IndiGenomes: a comprehensive resource of genetic variants from over 1000 Indian genomes. Nucleic Acids Res. 49, D1225–D1232 (2021).
  Medline CASGoogle Scholar
• 21. 1000 Genomes Project Consortium A, Auton A, Brooks LD et al. A global reference for human genetic variation. Nature 526, 68–74 (2015).
  MedlineGoogle Scholar
• 22. Chen X, Shen F, Gonzaludo N et al. Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data. Pharmacogenomics J. 21, 251–261 (2021).
  MedlineGoogle Scholar
• 23. Whirl-Carrillo M, McDonagh EM, Hebert JM et al. Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther. 92, 414–417 (2012).
  Medline CASGoogle Scholar
• 24. Preeprem T, Gibson G. SDS, a structural disruption score for assessment of missense variant deleteriousness. Front. Genet. 5, 82 (2014).
  MedlineGoogle Scholar
• 25. Dehouck Y, Kwasigroch JM, Gilis D, Rooman M. PoPMuSiC 2.1: a web server for the estimation of protein stability changes upon mutation and sequence optimality. BMC Bioinformatics 12, 1–12 (2011).
  MedlineGoogle Scholar
• 26. van Durme J, Delgado J, Stricher F, Serrano L, Schymkowitz J, Rousseau F. A graphical interface for the FoldX forcefield. Bioinformatics 27, 1711–1712 (2011).
  Medline CASGoogle Scholar
• 27. Kuznetsov IB, McDuffie M. FlexPred: a web-server for predicting residue positions involved in conformational switches in proteins. Bioinformation 3, 134–136 (2008).
  MedlineGoogle Scholar
• 28. Wass MN, Kelley LA, Sternberg MJE. 3DLigandSite: predicting ligand-binding sites using similar structures. Nucleic Acids Res. 38, W469 (2010).
  Medline CASGoogle Scholar
• 29. Nimrod G, Glaser F, Steinberg D, Ben-Tal N, Pupko T. In silico identification of functional regions in proteins. Bioinformatics 21(Suppl. 1), i328–i337 (2005).
  Medline CASGoogle Scholar
• 30. Chang X, Wang K. wANNOVAR: annotating genetic variants for personal genomes via the web. J. Med. Genet. 49, 433 (2012).
  MedlineGoogle Scholar
• 31. Grantham R. Amino acid difference formula to help explain protein evolution. Science (80-) 185, 862–864 (1974).
  Medline CASGoogle Scholar
• 32. Rowland P, Blaney FE, Smyth MG et al. Crystal structure of human cytochrome P450 2D6. J. Biol. Chem. 281, 7614–7622 (2006).
  Medline CASGoogle Scholar
• 33. Šali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779–815 (1993).
  Medline CASGoogle Scholar
• 34. Shapovalov MV, Dunbrack RL. A smoothed backbone-dependent rotamer library for proteins derived from adaptive kernel density estimates and regressions. Structure 19, 844 (2011).
  Medline CASGoogle Scholar
• 35. Wang A, Savas U, Hsu MH, Stout CD, Johnson EF. Crystal structure of human cytochrome P450 2D6 with prinomastat bound. J. Biol. Chem. 287, 10834 (2012).
  Medline CASGoogle Scholar
• 36. Malde AK, Zuo L, Breeze M et al. An automated force field topology builder (ATB) and repository: version 1.0. J. Chem. Theory Comput. 7, 4026–4037 (2011).
  Medline CASGoogle Scholar
• 37. Angélil R, Diemand J, Tanaka KK, Tanaka H. Homogeneous SPC/E water nucleation in large molecular dynamics simulations. J. Chem. Phys. 143(6), 64507 (2015).
  Google Scholar
• 38. Schmid N, Eichenberger AP, Choutko A et al. Definition and testing of the GROMOS force-field versions 54A7 and 54B7. Eur. Biophys. J. 40, 843–856 (2011).
  Medline CASGoogle Scholar
• 39. Maciej S, Becker FG, Cleary M et al. LINCS: a linear constraint solver for molecular simulations. J. Comput. Chem. 18, 1463–1472 (1997).
  Google Scholar
• 40. Parrinello M, Rahman A. Polymorphic transitions in single crystals: a new molecular dynamics method. J. Appl. Phys 52, 7182 (1998).
  Google Scholar
• 41. Pettersen EF, Goddard TD, Huang CC et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70 (2021).
  Medline CASGoogle Scholar
• 42. Fukuyoshi S, Kometani M, Watanabe Y et al. Molecular dynamics simulations to investigate the influences of amino acid mutations on protein three-dimensional structures of cytochrome P450 2D6.1, 2, 10, 14A, 51, and 62. PLOS ONE 11(4), e0152946 (2016).
  MedlineGoogle Scholar
• 43. Montané Jaime LK, Paul J, Lalla A, Legall G, Gaedigk A. Impact of CYP2D6 on venlafaxine metabolism in Trinidadian patients with major depressive disorder. Pharmacogenomics 19, 197–212 (2018).
  Google Scholar
• 44. Dodgen TM, Hochfeld WE, Fickl H et al. Introduction of the AmpliChip CYP450 test to a South African cohort: a platform comparative prospective cohort study. BMC Med. Genet. 14, 1–15 (2013).
  MedlineGoogle Scholar
• 45. Evert B, Griese EU, Eichelbaum M. A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine. Naunyn Schmiedeberg'sArch. Pharmacol. 350, 434–439 (1994).
  Medline CASGoogle Scholar
• 46. Lek M, Karczewski KJ, Minikel EV et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016).
  Medline CASGoogle Scholar
• 47. Don CG, Smieško M. Microsecond MD simulations of human CYP2D6 wild-type and five allelic variants reveal mechanistic insights on the function. PLOS ONE 13(8), e0202534 (2018).
  MedlineGoogle Scholar
• 48. Handa K, Nakagome I, Yamaotsu N, Gouda H, Hirono S. In silico study on the inhibitory interaction of drugs with wild-type CYP2D6.1 and the natural variant CYP2D6.17. Drug Metab. Pharmacokinet. 29, 52–60 (2014).
  Medline CASGoogle Scholar
• 49. Muroi Y, Saito T, Takahashi M et al. Functional characterization of wild-type and 49 CYP2D6 allelic variants for N-desmethyltamoxifen 4-hydroxylation activity. Drug Metab. Pharmacokinet. 29, 360–366 (2014).
  MedlineGoogle Scholar
• 50. Stern S, Hyland PL, Pacanowski M, Schuck R. Leveraging in vitro models for clinically relevant rare CYP2D6 variants in pharmacogenomics. Drug Metab. Dispos. 52(3), 159–170 (2024).
  MedlineGoogle Scholar
• 51. Lauschke VM, Ingelman-Sundberg M. Emerging strategies to bridge the gap between pharmacogenomic research and its clinical implementation. NPJ Genomic Med. 5, 9 (2020).
  MedlineGoogle Scholar
• 52. Nakatsuka N, Moorjani P, Rai N et al. The promise of discovering population-specific disease-associated genes in South Asia. Nat. Genet. 49, 1403–1407 (2017).
  Medline CASGoogle Scholar